Lipid nanocapsules for transdermal delivery of ropivacaine: in vitro and in vivo evaluation

Add time:07/25/2019    Source:sciencedirect.com

The objective of this research was to develop novel ropivacaine-loaded lipid nanocapsules (RPV-LNCs) and evaluate the potential of RPV-LNCs as external preparation for transdermal delivery. RPV-LNCs were prepared by phase inversion technique and optimized by response surface design. The permeation ability of RPV-LNCs was characterized both in vitro and in vivo. The results showed that the optimized RPV-LNCs represented typical core–shell structure with the mean diameter of 62.1 ± 1.7 nm. The entrapment efficiency and drug loading were 92.6 ± 1.3% and 1.35 ± 0.20%, respectively. Moreover, the cumulative amount of RPV penetrated through excised skin from LNCs was 2.17 folds than that of the propylene glycol. In vivo, RPV-LNCs contributed a higher RPV concentration in plasma (5.743 μg/mL). The RPV retained within dermis was 27.9 ± 5.2 μg/mL for LNCs, obviously remarkable than that of the propylene glycol group (15.6 ± 3.9 μg/mL). The skin histopathology study and scanning electron microscope (SEM) showed that interaction between LNCs and skin surface changed the apparent morphology of stratum corneum and broke the close conjugation of corneocyte layers. All the detailed evidence showed that LNCs could provide a promising tuning as a transdermal delivery system of ropivacaine.

We also recommend Trading Suppliers and Manufacturers of ROPIVACAINE RELATED COMPOUND B (50 MG) ((R)-(+)-1 -PROPYLPIPERIDINE-2-CARBOXYLIC ACID (2,6-DIMETHYLPHENYL)-AMIDE HYDROCHLORIDE MONOHYDRATE) (cas 112773-90-7). Pls Click Website Link as below: cas 112773-90-7 suppliers

Prev:Visceral mesh modified with cyclodextrin for the local sustained delivery of ropivacaine
Next:Ex vivo and in vivo diffusion of ropivacaine through spinal meninges: Influence of absorption enhancers)